Pharsight

Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226436 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US11413259 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10420735 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US11602508 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10159657 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10568850 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

Norepinephrine Bitartrate In 0.9% Sodium Chloride is owned by Nevakar Injectables.

Norepinephrine Bitartrate In 0.9% Sodium Chloride contains Norepinephrine Bitartrate.

Norepinephrine Bitartrate In 0.9% Sodium Chloride has a total of 6 drug patents out of which 0 drug patents have expired.

Norepinephrine Bitartrate In 0.9% Sodium Chloride was authorised for market use on 06 October, 2022.

Norepinephrine Bitartrate In 0.9% Sodium Chloride is available in solution;intravenous dosage forms.

Norepinephrine Bitartrate In 0.9% Sodium Chloride can be used as indicated to raise blood pressure in adult patients with severe, acute hypotension.

The generics of Norepinephrine Bitartrate In 0.9% Sodium Chloride are possible to be released after 30 January, 2038.

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 06 October, 2022

Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888534 INFORLIFE Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags
Apr, 2039

(15 years from now)

Norepinephrine Bitartrate In 0.9% Sodium Chloride is owned by Inforlife.

Norepinephrine Bitartrate In 0.9% Sodium Chloride contains Norepinephrine Bitartrate.

Norepinephrine Bitartrate In 0.9% Sodium Chloride has a total of 1 drug patent out of which 0 drug patents have expired.

Norepinephrine Bitartrate In 0.9% Sodium Chloride was authorised for market use on 15 September, 2022.

Norepinephrine Bitartrate In 0.9% Sodium Chloride is available in solution;intravenous dosage forms.

The generics of Norepinephrine Bitartrate In 0.9% Sodium Chloride are possible to be released after 26 April, 2039.

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 15 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic